Clinical Trials Browser

Completed × INDUSTRY × vosaroxin × Clear all

NCT00252382 2018-09-24

Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC

Phase 2 Completed

31 enrolled 6 charts

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01191801 2018-08-22

VALOR

Phase 3 Completed

711 enrolled 15 charts

Other hematologic neoplasm

Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Myeloid, Acute

NCT00298896 2018-07-26

Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

Phase 2 Completed

55 enrolled 10 charts

Carcinoma, Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00541866 2018-01-09

Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans

Phase 1/2 Completed

110 enrolled 15 charts

Other hematologic neoplasm

Leukemia, Neoplasms, Recurrence, Leukemia, Myeloid, Acute

NCT00607997 2017-06-28

Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

Phase 2 Completed

113 enrolled 25 charts

MyeloidOther hematologic neoplasm

Acute Disease, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT00246662 2017-03-30

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00091585 2007-05-10

Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

Phase 1 Completed

Neoplasms

NCT00094159 2007-05-10

Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

Phase 1 Completed

Neoplasms